Characterization and relevance of different diabetic retinopathy phenotypes

Developments in Ophthalmology

Volumn 39, Issue , 2007, Pages 13-30

  Cunha Vaz, J ^a,b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETIC RETINOPATHY; DISEASE COURSE; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; PATHOLOGY; PHENOTYPE; RETINA; REVIEW;

DIABETIC RETINOPATHY; DISEASE PROGRESSION; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; PHENOTYPE; RETINA;

EID: 33947524559     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000098497     Document Type: Review

References (27)

1. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Kein R: Diabetic retinopathy. Diabetes Care 1998;21:143-156.
2. Cunha-Vaz JG: Perspectives in the treatment of diabetic retinopathy. Diabetes Metab Rev 1992;8:105-116.
3. Cunha-Vaz JG: Pathophysiology of diabetic retinopathy. Br J Ophthalmol 1978;62:351-355.
4. Cogan DG, Kwabara T: Capillary shunts in the pathogenesis of diabetic retinopathy. Diabetes 1963;12:293-300.
5. Gardiner TW, Aiello LP: Pathogenesis of diabetic retinopathy; in Flynn HW Jr, Smiddy WE (eds): Diabetes and Ocular Disease: Past, Present, and Future Therapies. AAO Monogr No 14. San Francisco, The Foundation of the American Academy of Ophthalmology, 2000, pp 1-17.
6. Lobo CL, Bernardes RC, Figueira JP, Faria de Abreu JR, Cunha-Vaz JG. Three-year follow-up of blood-retinal barrier and retinal thickness alterations in patients with type 2 diabetes mellitus and mild nonproliferative diabetic retinopathy. Arch Ophthalmol 2004;122:211-217.
7. Lobo CL, Bernardes RC, Santos FJ, Cunha-Vaz JG: Mapping retinal fluorescein leakage with confocal scanning laser fluorometry of the human vitreous. Arch Ophthalmol 1999;117:631-637.
8. Fritsche P, Van der Heijde R, Suttorp-Schulten MSA, Pollack BC: Retinal thickness analysis (RTA). An objective method to assess and quantify the retinal thickness in healthy controls and diabetics without diabetic retinopathy. Retina 2002;22:768-771.
9. Grange JD: Retinopathie Diabétique. Rapport à la Société Française d'Ophthalmologie. Paris, Masson, 1995.
10. Rema M, Saravanan G, Deepa R, Mohan V: Familial clustering of diabetic retinopathy in South Indian Type 2 diabetic patients. Diabet Med 2002;19:910-916.
11. Diabetes Control and Complications Trials Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2569.
12. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR, the UKPDS Group: UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-163.
13. 1c levels are genetically determined even in type 1 diabetes. Evidence from healthy and diabetic twins. Diabetes 2001;50:2858-2863.
14. Ribeiro ML, Seres AI, Carneiro AM, Stur M, Zourdani A, Caillon P, Cunha-Vaz JG and on behalf of the DX-Retinopathy Study Group: Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Grafe's Arch Clin Exp Ophthalmol 2006; DOI 10.1007/s00417-006-0318-2.
15. Rogus JJ, Warram JH, Krolewski AS: Genetic studies of late diabetic complications: the overlooked importance of diabetes duration before complication onset. Diabetes 2002;51:1655-1662.
16. Warpeha KM, Chakravarthy U: Molecular genetics of microvascular disease in diabetic retinopathy. Eye 2003;17:305-311.
17. Humphries SE, Talmud PH, Montgomery H: Gene-environment interaction: lipoprotein lipase and smoking and risk of CAD and the ACE and exercise-induced left ventricular hypertrophy as examples; in Malcom S, Gooship J (eds): Genotype to Phenotype. Oxford, Bios Scientific, 2001, pp 55-72.
18. Wasgenknecht LE, Bowden DW, Carr JJ, Langefeld CD, Freedman BI, Rich SS: Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes 2001;50:861-866.
19. Fong DS, Ferris F: Practical management of diabetic retinopathy. Focal Point 2003;21:1-17.
20. Greene DA, Lattimer SA, Sima AAF: Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987;316:599-606.
21. Brownlee M: Glycation and diabetic complications (Lilly lecture 1993). Diabetes 1994;43:836-841.
22. Clermont AC, Aiello LP, Mori F, Aiello LM, Bursell SE: Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. Am J Ophthalmol 1997;124:433-436.
23. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC X inhibitor. Science 1996;272:728-731.
24. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW, Penn State Retina Research Group: Vascular permeability in experimental diabetes is associated with reduced endothelial occluding content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 1998;47:1953-1959.
25. Adamis AP: Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002;86:363-365.
26. Weinberg RN, Friedman DS, Fechtner RD, et al: Risk assessment in the management of patient with ocular hypertension. Am J Opthalmol 2004;138:458-467.
27. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.